WADA 2026 Prohibited List: What Changed for Peptides

Every January, the World Anti-Doping Agency (WADA) Prohibited List comes into force for the year, and every January the peptide community asks the same thing: did anything change for us? The 2026 List took effect on 1 January 2026. This article walks through what it actually changed for peptide hormones and the recovery/GH peptides athletes care about — verified directly against WADA's own 2026 Summary of Major Modifications and Explanatory Notes¹ — and, just as importantly, what it did not change.

The honest headline up front: for peptides, the 2026 List is a quiet year. WADA added exactly one new peptide-class example (an EPO-mimetic), clarified that two weight-loss drugs are being monitored (not banned), and otherwise left the architecture that already prohibits GH-releasing peptides and BPC-157 exactly where it was. Nothing here is doping advice — this is a compliance and detection explainer. If you compete in a tested sport, the practical rule hasn't moved: these substances were prohibited in 2025 and remain prohibited in 2026.

How the List is structured (so the changes make sense)

The Prohibited List groups substances into numbered classes. The one that captures most performance peptides is S2 — "Peptide hormones, growth factors, related substances, and mimetics." S2 is non-exhaustive: it bans whole families (erythropoietin-receptor agonists, growth hormone and its releasing factors and secretagogues, growth factors that affect muscle/tendon/vascularization) and then lists named examples. A peptide doesn't need to appear by name to be banned — if it belongs to a prohibited class or is a "mimetic" of one, it's covered. That "named class plus examples" design is why most year-to-year changes are additions of examples, not new categories.

Two other anchors matter for peptides. S0 covers any pharmacological substance with no current regulatory approval for human therapeutic use (no marketing authorization anywhere) — that's the bucket that catches research-only peptides like BPC-157. And the Monitoring Program sits outside the Prohibited List: it tracks substances WADA wants usage data on, which are not prohibited while monitored.

What actually changed in 2026 for peptides

Reading WADA's 2026 Summary of Modifications, the peptide-relevant edits are short and specific¹:

• •S2 — one addition: pegmolesatide, added "as an example of a new EPO-mimetic agent"¹. Pegmolesatide is a synthetic peptide-based erythropoietin-receptor agonist — an EPO mimetic that boosts red-cell production and therefore endurance. It was already prohibited as a member of the EPO-mimetic class; naming it just makes that explicit. EPO-mimetic peptides as a category have been detectable in urine by mass spectrometry for years⁸, so this is a labeling clarification, not a new loophole closing.
• •Monitoring Program — GLP-1 clarification: WADA clarified that "the urine monitoring of semaglutide includes also the monitoring of tirzepatide"¹. This is the change most likely to be misread. Semaglutide and tirzepatide are not prohibited. They sit in the Monitoring Program, which means WADA is collecting anonymized usage data in- and out-of-competition to decide whether misuse warrants future action — exactly the pathway a substance travels before any ban is considered.

That's it for the S2/peptide world in 2026. There was no new growth-hormone-secretagogue entry, no new GH-releasing-peptide threshold, and no change to how GH peptides or BPC-157 are classified. They didn't need one — they were already prohibited.

A couple of adjacent edits are worth a tested athlete's attention even though they aren't peptides: WADA clarified that esters of prohibited anabolic steroids are also prohibited (closing an "it's a different ester" argument), and it added the synthetic supplement adulterants α-naphthoflavone (an aromatase inhibitor) and BAM15 (an AMPK activator) as named examples after finding them in supplements¹. That supplement-contamination thread runs straight through the peptide grey market too.

The GLP-1 question, answered honestly

Because semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are everywhere right now, the 2026 monitoring clarification gets framed online as "WADA banned Ozempic." It did not. Monitoring is the opposite of a ban — it's surveillance to gather evidence. As of the 2026 List, a GLP-1 receptor agonist used for legitimate metabolic reasons is not a Prohibited Substance, and an athlete is not committing an anti-doping rule violation by being on one (subject, as always, to the actual product's contents and any sport-specific rules).

The honest caveat: monitoring status is not permanent. WADA monitors a substance precisely because it's weighing whether the performance or body-composition effects cross a line. The 2026 expansion to capture tirzepatide alongside semaglutide signals the class is under active watch. If you compete, "monitored, not banned" is the correct status today — but it's a status that exists because a future change is on the table.

One important distinction within the GLP-1 family: monitoring applies only to the approved drugs. The next-generation triple agonist retatrutide (GLP-1/GIP/glucagon) is not monitored and not in some grey zone — because it is unapproved, it falls under S0 and is prohibited at all times, exactly like other research-only peptides. We cover that, and why its impressive Phase 2 weight-loss data doesn't change the rule for tested athletes, in retatrutide for athletes.

What's already banned — and how it's detected

The reason 2026 looks quiet for peptides is that the heavy lifting happened years ago. The relevant families are already prohibited, and detection science has been catching up substance by substance:

• •GH secretagogues and GH-releasing peptides (the GHRP-2/GHRP-6/hexarelin/ipamorelin family) are S2-prohibited, and WADA-accredited labs have published, validated methods that find their urinary metabolites after administration². There are dedicated, advancing assays for GHRH synthetic analogs (the tesamorelin/CJC-1295/sermorelin family)³, including newer nano-LC high-resolution methods for GHRH and its analogs in urine⁴.
• •Growth hormone itself is policed two ways: a direct "isoform" immunoassay, and an indirect biomarker approach. The biomarker (GH-2000) method tracks downstream markers — IGF-I and the N-terminal propeptide of type III procollagen (P-III-NP) — to flag GH use even when the hormone has cleared; longitudinal monitoring of these markers meaningfully extends the detection window versus a single decision limit⁵⁶. WADA has even adapted the Athlete Biological Passport logic — building an individual's own longitudinal baseline and flagging deviations — to the detection of GH doping⁷. This is the "indirect detection" principle: you don't have to catch the molecule, you can catch its fingerprint.
• •The myostatin/follistatin axis — the muscle-growth pathway targeted by follistatin and ACE-031–type agents (we cover the molecules in myostatin-inhibitor peptides: follistatin and ACE-031) — is a recognized doping target with detection science of its own. Labs have published methods to detect follistatin-based inhibitors of TGF-β signaling in serum/plasma⁹, and researchers are profiling serum myokines as biomarkers of myostatin inhibition to build indirect tests for this axis¹⁰. So the follistatin/myostatin "biomarker detection" angle is real and developing — though, honestly, it is earlier-stage than the mature GH and EPO assays.
• •BPC-157 sits in S0 (no approved human therapeutic use) and is prohibited at all times. The 2026 List didn't touch this, and — a point worth stressing — neither does any change in US compounding rules. We unpack that mismatch in the 2026 FDA peptide reclassification: a domestic regulatory shift does not alter a substance's WADA status.

The practical upshot for a tested athlete is the one we make throughout this site: "probably won't show up" is not a defense, because detection windows, biomarker passports, and metabolite assays keep widening. For the full picture of which peptides register on which tests, see do peptides show up on drug tests?.

The contamination angle the List quietly underlines

One thread in the 2026 modifications is easy to skip but directly relevant to anyone buying grey-market peptides: WADA explicitly added α-naphthoflavone and BAM15 because they were found in supplements¹. Anti-doping bodies treat contaminated and adulterated products as a serious, documented route to a positive test — the literature maps contamination as a real source of inadvertent exposure to prohibited substances¹¹. "Research use only" peptides usually carry no trustworthy certificate of analysis, so what's in the vial — and therefore what's in your sample — isn't something you control. That's a recurring theme in our look at whether GH peptides are safe and legal.

The bottom line

For peptides, the WADA 2026 Prohibited List is an incremental year, not a turning point. The only S2 addition was pegmolesatide, an EPO-mimetic that was already covered by class; the only GLP-1 news was a monitoring clarification, not a ban; and the structures that prohibit GH-releasing peptides, GH secretagogues, and BPC-157 were already in place and unchanged¹. The real story isn't a new rule — it's that detection keeps maturing: metabolite assays for GH-releasing peptides², biomarker and passport approaches for GH⁵⁷, and emerging methods across the EPO-mimetic⁸ and follistatin/myostatin⁹¹⁰ frontiers. If you compete in a tested sport, treat the entire performance-peptide category as prohibited and assume it's findable. For how the products themselves compare on evidence and oversight, start with the best recovery peptides hub and our pillar on peptides for recovery and healing. Always check your own sport's current rules and the live List before acting — this explainer reflects the 2026 List as published, not personalized anti-doping advice.